Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of JNJ-67864238 in moderately to severely active Crohn's disease
2019-003335-37Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing JNJ-67864238 with Placebo (2 arms). Primary endpoints: Change from baseline in Crohn's Disease Activity Index score at Week 12 and Change from baseline in Simplified Endoscopic Score for Crohn's Disease at Week 12. Started Nov 2019; status: terminated.
02
Drugs
PTG-200
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-003335-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003335-37.